We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Test for Cardiac Protein Diagnoses Heart Attack

By LabMedica International staff writers
Posted on 17 Nov 2011
A novel blood test for a cardiac biomarker has been used to determine whether a patient has had a heart attack. More...


The test measures a large protein known as cardiac myosin binding protein-C (cMyBP-C), which is released into the blood following a cardiac event.

Scientists at Loyola University Chicago (Maywood, IL, USA) quantified plasma levels of cMyBP-C by a sandwich enzyme-linked immunosorbent assay (ELISA) using capture monoclonal anti-cMyBP-C, E7 and a detection rabbit polyclonal antibody anti-cMyBP-CC0–C1. Plasma cardiac troponin (cTnI) levels were also measured by a commercial sandwich ELISA. To determine the sensitivity of the sandwich ELISA for cMyBP-C, the investigators defined the limit of detection values and quantification for lower and upper limits. The values of lower limit of quantification and upper limit of quantification were 0.02 ng/ml and 2,053 ng/ml, respectively.

Plasma samples were collected from 16 myocardial infarction) MI) patients and 11 normal healthy controls. Importantly, cMyBP-C and cTnI levels in the plasma samples of healthy controls were very low, 0.95 ± 0.34 ng/mL and 0.238 ± 0.07 ng/mL, respectively. Strikingly, the concentration of cMyBP-C in the plasma of MI patients was significantly increased to 227 ± 50 ng/mL, compared to controls and greater than plasma cTnI levels at 30 ± 9 ng/mL. The anti-cMyBP-C, E7 monoclonal antibody used in this study is a product Santa Cruz Biotechnology (Santa Cruz, CA, USA). The human cardiac troponin assay was produced by Calbiotech (San Diego, CA, USA).


Sakthivel Sadayappan, PhD, senior author of the study said, "This potentially could become the basis for a new test, used in conjunction with other blood tests, to help diagnose heart attacks. This is the beginning. A lot of additional studies will be necessary to establish cMyBP-C as a true biomarker for heart attacks." The authors concluded that future studies would determine the time course of release, peak concentrations, and half-life in the circulatory system. The study was available online since September 19, 2011, in the Journal of Molecular and Cellular Cardiology.

Related Links:
Loyola University Chicago
Santa Cruz Biotechnology
Calbiotech



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automated Urinalysis Solution
UN-9000
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.